USA flag logo/image

An Official Website of the United States Government

A Novel RNA Replication Based Mammalian Expression System

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
96209
Program Year/Program:
2010 / SBIR
Agency Tracking Number:
GM093423
Solicitation Year:
N/A
Solicitation Topic Code:
NIGMS
Solicitation Number:
N/A
Small Business Information
EXON BIOSYSTEMS
6650 LUSK BLVD, SUITE B108 SAN DIEGO, CA 92121
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2010
Title: A Novel RNA Replication Based Mammalian Expression System
Agency: HHS
Contract: 1R43GM093423-01
Award Amount: $162,668.00
 

Abstract:

DESCRIPTION (provided by applicant): The purpose of this initiative is to develop a novel technology for the expression of authentic glycoproteins. Many proteins become post-translationally modified during the secretory process. These modifications are ext remely important because they may alter the proteins' physical and chemical properties, folding, stability, and activity. These glycosylated proteins are often the targets of drug discovery. Therefore, it is highly desirable to develop an expression system that is fast and highly productive for authentic glycosylated proteins. We propose here to develop a unique mammalian expression system by introducing an RNA dependent RNA polymerase derived from Semliki Forest Virus to amplify the transgene RNA and provi de an extra step in the natural transcription- translation process of protein production. The massive amplification of the target gene RNA makes the expression system highly efficient and reliable. Our expression system will inherit the intrinsic replicati on function of viral RNA dependent RNA polymerase and meanwhile, no viral structure protein or its RNA is involved in our system. Therefore, it is ultimately a safe system. With this system we can produce authentic glycosylated proteins for research, drug discovery and preclinical, and eventually, therapeutic glycosylated proteins and vaccine as well. PUBLIC HEALTH RELEVANCE: Most of the recombinant protein drugs are modified in the cell after being synthesized. It is necessary to make authentically modified proteins for drug development, drug production and disease related research. However, production of the authentically modified protein is a bottleneck for the drug development and production. In this proposal, we presented a novel and unique appro ach to design a mammalian expression system that is capable to produce milligram quantity of authentically modified proteins. Taken advantage of the RNA dependent RNA polymerase (RdRP) from Semliki Forest virus, the recombinant protein gene will be amplifi ed at RNA stage. The massive amplified RNA will take over the protein synthesis machinery and effectively produce large amount of recombinant protein. The novel system will meet the demand of drug development and preclinical studies.

Principal Investigator:

Kunhua K. Chen

Business Contact:

Chen Kunhua
Small Business Information at Submission:

EXON BIOSYSTEMS
6650 LUSK BLVD, SUITE B108 SAN DIEGO, CA 92121

EIN/Tax ID: 120802086
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No